Area of research
Hepatology · Epidemiology
Research interest
Research interests include Liver Disease Diagnosis and Treatment, Liver Disease and Transplantation, Hepatitis C virus research, and Hepatocellular Carcinoma Treatment and Prognosis.
Do We Still Need a BCLC-Intermediate Stage for Hepatocellular Carcinoma-Management?
An International Phase 4 Study of Lenvatinib and Sorafenib in Real-World Patients with Unresectable Hepatocellular Carcinoma: Final Analysis
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
Preliminary qualification of a machine learning-based assessment of the tumor immune infiltrate as a predictor of outcome in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
Development of Liver-Heart Score for Early Detection of Myocardial Contractile Dysfunction in Cirrhosis by Strain Imaging.
Severe alpha-1 antitrypsin deficiency is associated with a higher risk of complications after first decompensation than other aetiologies of cirrhosis.
Long-term survival benefit of atezolizumab/bevacizumab treatment in unresectable HCC patients.
Direct-acting antiviral therapies for hepatitis C infection: global registration, reimbursement, and restrictions
Evaluation of prognostic scores in patients with HCC undergoing first-line immunotherapy with atezolizumab and bevacizumab
Editorial: Prediction of decompensation/death in advanced chronic liver disease with vWF: Non-invasive vascular factors trump liver function.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma.
Securing wider EU commitment to the elimination of hepatitis C virus.
Regional Differences in Clinical Presentation and Prognosis of Patients With Post–Sustained Virologic Response Hepatocellular Carcinoma
MAFLD, HCC and the dilemma of (changing) terminology in liver diseases.
Factors Affecting the Learning Curve in the Endoscopic Ultrasound-Guided Sampling of Solid Pancreatic Lesions: A Prospective Study.
Textbook Outcome After Trans-arterial Chemoembolization for Hepatocellular Carcinoma
Limited access to liver transplantation and TIPS despite high mortality, healthcare resource use and costs of cirrhosis in Germany.
Progress of Hepatitis C elimination in Viennese people living with HIV after two decades of increasing cure rates.
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.
Outcome of liver cancer patients with SARS-CoV-2 infection: An International, Multicentre, Cohort Study.
Changing Epidemiological Trends of Hepatobiliary Carcinomas in Austria 2010-2018.
Hepatocellular carcinoma incidence in chronic hepatitis C patients according to sustained virological response (<scp>SVR</scp>) with interferon‐based therapies and baseline characteristics
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
NASH limits anti-tumour surveillance in immunotherapy-treated HCC.
Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score
Assessing the impact of COVID-19 on liver cancer management (CERO-19)
The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model
The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria.